Today, we’re excited to announce our $7.2M seed round alongside a strategic collaboration with @PacBio! At Blank Bio, we help pharma make more informed decisions in clinical trials by capturing the biology that makes each patient’s tumour unique. We do this by training RNA foundation models to learn the patterns that shape disease progression and how patients respond to treatment. In our collaboration with @PacBio, we will generate long-read, bulk RNA-sequencing data from patient tumour samples across multiple indications. This dataset will be used to further train and evaluate our models. Our models are currently focused on two main applications. First, we predict how a patient’s disease is likely to progress over time from their molecular profile. Through the FDA-recommended approach of covariate adjustment, these RNA prognostic scores can help clinical development teams design trials that reach statistical power with fewer patients. Second, we’re working to help pharma teams understand biological differences between patients so they can identify who is most likely to respond to a given therapy. We are thankful to @definevc, @LeonisCapital, Nova Threshold, @ripple_ventures, @SignalFire, @ycombinator, and other investors for being early supporters in our vision. This financing will support the continued development of our foundation models, expanded collaborations with pharma, and growing our patient-level datasets. Read the press release: blank.bio/seed-announcement Read the blog from the team: blank.bio/accelerate-clinica… Learn more about Blank Bio: blank.bio